Omeros (OMER) Other financing activities (2010 - 2024)

Omeros (OMER) reported Other financing activities of $115.5 million for Q1 2024, up 5204.18% sequentially from $2.2 million in Q3 2020.

Omeros (OMER) Other financing activities (2010 - 2024) Analysis & Trends

Omeros (OMER) has 10 years of Other financing activities data on file, last reported at $115.5 million in Q1 2024.

For the quarter ending Q1 2024, Other financing activities changed N/A year-over-year to $115.5 million; the trailing twelve-month figure through Dec 2024 stood at $115.5 million (changed N/A YoY), and the FY2024 full-year result was $115.5 million, changed N/A from the prior year.
Other financing activities grew to $115.5 million in Q1 2024, from $2.2 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $115.5 million in Q1 2024 to a low of $88000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn

Download Data